Current risk stratification strategies are insufficient to appropriately identify which patients have a greater likelihood of developing poor outcomes. This is why we are conducting this project with the goal of creating better tools to identify those most at risk and rapidly give them the appropriate care. Research has shown that tests based on biomarker levels are just as good or better than our current methods to predict the risk of poor outcomes. This is because biomarker levels are a measurable quantity whereas the current methods depend on observations based on symptoms which can be subjective. In addition, the biomarker test we are developing is based on a protein that is released early in the course of most common infections, which gives it the advantage of getting results fast and independently of the type of infection, to quickly make decisions that will result in improving the health of newborns. See scientific publications to read more about this research.